Skip to main content
Richard Scranton, MD, Internal Medicine, Boston, MA

RichardEScrantonMD

Internal Medicine Boston, MA

Physician

Dr. Scranton is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Scranton's full profile

Already have an account?

  • Office

    1620 Tremont Street
    Brigham And Womens Hospital Division Of Aging
    Boston, MA 02120
    Phone+1 617-525-7631

Education & Training

  • Naval Medical Center (Portsmouth)
    Naval Medical Center (Portsmouth)Residency, Internal Medicine, 1994 - 1997
  • East Tennessee State University James H. Quillen College of Medicine
    East Tennessee State University James H. Quillen College of MedicineClass of 1994

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2000 - 2018

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Lyndra Therapeutics Doses First Clinical Trial Participant in Pivotal Study of Oral Weekly Risperidone (LYN-005) for Schizophrenia and Schizoaffective Disorder
    Lyndra Therapeutics Doses First Clinical Trial Participant in Pivotal Study of Oral Weekly Risperidone (LYN-005) for Schizophrenia and Schizoaffective DisorderMay 9th, 2023
  • Lyndra Therapeutics’ Investigational Oral, Weekly Opioid Use Disorder Treatment LYN-014 Granted Fast Track Designation by FDA
    Lyndra Therapeutics’ Investigational Oral, Weekly Opioid Use Disorder Treatment LYN-014 Granted Fast Track Designation by FDAJuly 27th, 2021
  • Lyndra Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for Lyndra’s Weekly Risperidone (LYN-005) for the Treatment of Adults with Schizophrenia and Other Indications
    Lyndra Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for Lyndra’s Weekly Risperidone (LYN-005) for the Treatment of Adults with Schizophrenia and Other IndicationsJuly 19th, 2021
  • Join now to see all